X0206 3 2014-05-02 0 0001178253 SCYNEXIS INC SCYX 0001163156 ALTA BIOPHARMA PARTNERS II LP ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 0001163189 ALTA BIOPHARMA MANAGEMENT II LLC ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 0001163157 ALTA EMBARCADERO BIOPHARMA PARTNERS II LLC ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 0001198321 CHAMPSI FARAH ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 Common Stock Warrant (right to buy) 0.20 2011-12-07 2016-12-06 Common Stock 4551 D Common Stock Warrant (right to buy) 0.20 2012-05-15 2017-05-14 Common Stock 4551 D Common Stock Warrant (right to buy) 0.20 2013-12-11 2018-12-10 Common Stock 82454 D Common Stock Warrant (right to buy) 0.20 2011-12-07 2016-12-06 Common Stock 174 I By Alta Embarcadero BioPharma Partners II, LLC Common Stock Warrant (right to buy) 0.20 2012-05-15 2017-05-14 Common Stock 174 I By Alta Embarcadero BioPharma Partners II, LLC Common Stock Warrant (right to buy) 0.20 2013-12-11 2018-12-10 Common Stock 3033 I By Alta Embarcadero BioPharma Partners II, LLC Series C Preferred Stock 2002-06-19 Common Stock 161238 D Series C Preferred Stock 2002-06-19 Common Stock 5931 I By Alta Embarcadero BioPharma Partners II, LLC Series D-1 Preferred Stock 2013-12-11 Common Stock 50239 D Series D-1 Preferred Stock 2013-12-11 Common Stock 1848 I By Alta Embarcadero BioPharma Partners II, LLC Series D-2 Preferred Stock 2013-12-11 Common Stock 69476 D Series D-2 Preferred Stock 2013-12-11 Common Stock 2642 I By Alta Embarcadero BioPharma Partners II, LLC Farah Champsi (known as the "Principal") is the managing director of Alta BioPharma Management II, LLC ("ABM II") (which is the general partner of Alta BioPharma Partners II, L.P. ("ABP II")), and manager of Alta Embarcadero BioPharma Partners II, LLC ("AEBP II"). As managing director and manager of such entities, Ms. Champsi may be deemed to have voting and investment power for the shares held by ABP II and AEBP II. The Principal disclaims beneficial ownership of all such shares held by ABP II and AEBP II, except to the extent of her proportionate pecuniary interests therein. These securities are held by AEBP II. Each of the Series C Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-3.536 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date. Each of the Series D-1 Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-20.4 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date. Each of the Series D-2 Preferred Stock is convertible into Common Stock of the Issuer on a 1-for-20.4 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date. By: /s/ Farah Champsi, Managing Director 2014-05-02